Overview

A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate symptomatic remission rate in patients with schizophrenia using long acting risperidone microspheres
Phase:
Phase 4
Details
Lead Sponsor:
Janssen Korea, Ltd., Korea
Treatments:
Risperidone